Core Insights - Pacific Biosciences of California (PACB) reported a quarterly loss of $0.12 per share, better than the Zacks Consensus Estimate of a loss of $0.16, marking an earnings surprise of +25.00% [1] - The company posted revenues of $38.44 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 3.51% and down from $39.97 million a year ago [2] - The stock has gained approximately 9.3% since the beginning of the year, underperforming the S&P 500's gain of 15.1% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.17 on revenues of $41.98 million, and for the current fiscal year, it is -$0.56 on revenues of $158.66 million [7] - The estimate revisions trend for Pacific Biosciences was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Instruments industry, to which Pacific Biosciences belongs, is currently in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]